Abnormalities in serum chemokine levels in euthymic patients with Bipolar Disorder

Brain, Behavior, and Immunity

Volumn 23, Issue 8, 2009, Pages 1079-1082

  Brietzke, Elisa ^b   Kauer Sant'Anna, Márcia ^a,b   Teixeira, Antônio Lúcio ^c   Kapczinski, Flávio ^a,b  

^a Laboratory of Molecular Psychiatry   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c Institute of Biological Sciences   (Brazil)

Author keywords

Allostatic load; Bipolar disorder; Chemokine CXCL10; Chemokine CXCL24; Chemokines; Cytokines; Depressive episode; Inflammatory mediators; Mania; Neuroplasticity

Indexed keywords

CCL10 CHEMOKINE; CCL9 CHEMOKINE; CHEMOKINE; CXCL11 CHEMOKINE; EOTAXIN; EOTAXIN 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 2; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; BIPOLAR I DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HAMILTON SCALE; HUMAN; MALE; NERVE CELL PLASTICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VOLUNTEER; YOUNG MANIA RATING SCALE;

ADULT; ANALYSIS OF VARIANCE; BIPOLAR DISORDER; CHEMOKINES, CC; CHEMOKINES, CXC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PSYCHIATRIC STATUS RATING SCALES;

EID: 72649084925     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2009.04.008     Document Type: Article

References (39)

1. Angst F., Stassen H.H., Clayton P.J., and Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J. Affect. Disord. 68 (2002) 167-181
2. Brietzke E., and Kapczinski F. TNF-alpha as a molecular target in bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008) 1355-1361
3. Charo I.F., and Ransohoff R.M. The many roles of chemokines and chemokines receptors in inflammation. N. Engl. J. Med. 354 (2006) 610-621
4. Drexhage R.C., Padmos R.C., de Wit H., Versnel M.A., Hooijkaas H., van der Lely A.J., van Beveren N., de Rijk R.H., and Cohen D. Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: association with the metabolic syndrome in patients?. Schizophr. Res. 102 (2008) 352-355
5. Gabbay V., Klein R.G., Alonso C.M., Babb J.S., Nishawala M., De Jesus G., Hirsh G., Hottinger-Blanc P.M.Z., and Gonzalez C.J. Immune system dysregulation in adolescent major depressive disorder. J. Affect. Disord. 115 (2009) 177-182
6. Galimberti D., Schoonenboom N., Scheltens P., Fenoglio C., Bouwman F., Venturelli E., Guidi I., Blankenstein M.A., Bresolin N., and Scarpini E. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch. Neurol. 63 (2006) 538-543
7. Ichiyama T., Okada K., Lipton J.M., Matsubara T., Hayashi T., and Furukawa S. Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NFkappaB. Brain Res. 857 (2000) 246-251
8. Huang T.L., and Lee C.T. T helper 1/T helper 2 cytokine imbalance and clinical phenotypes in acute-phase major depressive disorder. Psychiatry Clin. Neurosci. 61 (2007) 415-420
9. Kapczinski F., Frey B.N., Kauer-Sant'anna M., and Grassi-Oliveira R. Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev. Neurother. 8 (2008) 1101-1113
10. Kapczinski F., Vieta E., Andreazza A.C., Frey B.N., Gomes F.A., Tramontina J., Kauer-Sant'anna M., Grassi-Oliveira R., and Post R.M. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci. Biobehav. Rev. 32 (2008) 675-692
11. Kauer-Sant'anna M., Kapczinski F., Andreazza A.C., Bond D.J., Lam R.W., Trevor Young L., and Yatham L.N. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int. J. Neuropsychopharmacol. 4 (2008) 1-12
12. Kim Y.K., Myint A.M., Lee B.H., Han C.S., Lee H.J., Kim D.J., and Leonard B.E. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 28 (2004) 1229-1234
13. Kim Y.K., Jung H.G., Myiant A.M., Kim H., and Park S.H. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J. Affect. Disord. 104 (2007) 91-95
14. Kim T.S., Lim H.K., Lee J.Y., Kim D.J., Park S., Lee C., and Lee C.U. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease. Neurosci. Lett. 436 (2008) 196-200
15. Knijff E.M., Breunis M.N., Kupka R.W., de Wit H.J., Ruwhof C., Akkerhuis G.W., Nolen W.A., and Drexhage H.A. Bipolar Disord. 7 (2007) 743-753
16. Kupfer D.J. The increasing medical burden in bipolar disorder. JAMA 293 (2005) 2528-2530
17. Leitinger N. The role of phospholipid oxidation products in inflammatory and autoimmune diseases: evidence from animal models and in humans. Subcell. Biochem. 49 (2008) 325-350
18. Limatola C., Ciotti M.T., Mercanti D., Vacca F., Ragozzino D., Giovannelli A., Santoni A., Eusebi F., and Miledi R. The chemokine growth-related gene product beta protects rat cerebellar granule cells from apoptotic cell death through alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors. Proc. Natl. Acad. Sci. USA 97 (2000) 6197-6201
19. Limatola C., Lauro C., Catalano M., Ciotti M.T., Bertollini C., Di Angelantonio S., Ragozzino D., and Eusebi F. Chemokine CX3CL1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity. J. Neuroimmunol. 166 (2005) 19-28
20. Mackay C.R. Chemokines: immunology's high impact factors. Nat. Immunol. 2001 2 (2003) 95-101
21. McEwen B.S. Mood disorders and allostatic load. Biol. Psychiatry 54 (2003) 200-207
22. Merendino R.A., Di Pasquale G., De Luca F., Di Pasquale L., Ferlazzo E., Martino G., Palumbo M.C., Morabito F., and Gangemi S. Involvement of fractalkine and macrophage inflammatory protein-1 alpha in moderate-severe depression. Mediators Inflamm. 13 (2004) 205-207
23. Moreira M.A., Tilbery C.P., Monteiro L.P., Teixeira M.M., and Teixeira A.L. Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis. Acta Neurol. Scand. 114 (2006) 109-113
24. Murdoch C., and Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood 95 (2000) 3032-3043
25. Myint A.M., Leonard B.E., Steinbusch H.W., and Kim Y.K. Th1, Th2, and Th3 cytokine alterations in major depression. J. Affect. Disord. 88 (2005) 167-173
26. Nery F.G., Monkul E.S., Hatch J.P., Fonseca M., Zunta-Soares G.B., Frey B.N., Bowden C.L., and Soares J.C. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum. Psychopharmacol. 23 (2008) 87-94
27. O'Brien S.M., Scully P., Scott L.V., and Dinan T.G. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J. Affect. Disord. 90 (2006) 263-267
28. Pan W., and Kastin A.J. Penetration of neurotrophins and cytokines across the blood/brain/blood/spinal cord barrier. Adv. Drug Deliv. Rev. 36 (1999) 291-298
29. Post R. Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J. Psychiatr. Res. 41 (2007) 979-990
30. Ragozzino D., Di Angelantonio S., Trettel F., Bertollini C., Maggi L., Gross C., Charo I.F., Limatola C., and Eusebi F. Chemokine fractalkine/CX3CL1 negatively modulates active glutamatergic synapses in rat hippocampal neurons. J. Neurosci. 26 (2006) 10488-10498
31. Reale M., Iarlori C., Feliciani C., and Gambi D. Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease. J. Alzheimers Dis. 14 (2008) 147-159
32. Rostène W., Kitabgi P., and Parsadaniantz S.M. Chemokines: a new class of neuromodulator?. Nat. Rev. Neurosci. 8 (2007) 895-903
33. Schloesser R., Huang J., Klein P., and Manji H. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 33 (2008) 110-133
34. Simon N.M., McNamara K., Chow C.W., Maser R.S., Papakostas G.I., Pollack M.H., Nierenberg A.A., Fava M., and Wong K.K. A detailed examination of cytokine abnormalities in major depressive disorder. Eur. Neuropsychopharmacol. 18 (2008) 230-233
35. Soczynska, J., Kennedy, S.H., Goldstein, B.I., Lachowski, A., Woldeyohannes, H., McIntyre, R.S., in press. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? Neurotoxicology. doi:10.1016/j.neuro.2009.03.004.
36. Sutcigil L., Oktenli C., Musabak U., Bozkurt A., Cansever A., Uzun O., Sanisoglu S.Y., Yesilova Z., Ozmenler N., Ozsahin A., and Sengul A. Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin. Dev. Immunol. 2007 (2007) 76396
37. Takahashi K., Funata N., Ikuta F., and Sato S. Neuronal apoptosis and inflammatory responses in the central nervous system of a rabbit treated with Shiga toxin-2. J. Neuroinflamm. 5 (2008) 11
38. Teixeira A.L., Reis H.J., Nicolato R., Brito-Melo G., Correa H., Teixeira M.M., and Romano-Silva M.A. Increased serum levels of CCL11/eotaxin in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008) 710-714
39. Watson K., and Fan G.H. Macrophage inflammatory protein 2 inhibits β-amyloid peptide (1-42)-mediated hippocampal neuronal apoptosis through activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling pathways. Mol. Pharmacol. 67 (2005) 757-765